Glenmark Pharma.
Drug Manufacturers - Specialty & Generic · GLENMARK
Large CapHealthcareHigh Growth
Glenn Saldanha
Chairman and Managing Director · Visionary
Company DNA
Founder-Centric
About
Glenmark Pharma. is a Large Cap company in the Healthcare sector, listed on NSE as GLENMARK. With a market cap of ₹60K Cr and revenue of ₹13K Cr, it is currently in the High Growth phase. Known for its Founder-Centric culture and Disruptor approach to innovation, the company operates at a Startup-Speed pace. Glenn Saldanha exerts significant influence on the strategic direction, characteristic of the promoter-led pharma model where the vision is closely tied to the founder's leadership. Its strategic mandate: The company needs a visionary leader to pivot toward specialty and innovative drug portfolios to maintain growth in a competitive global pharma landscape.
FAQ
What kind of company is Glenmark Pharma.?
Glenmark Pharma. is a Large Cap Healthcare company (GLENMARK) in the High Growth phase with a market cap of ₹60K Cr. It is classified as Founder-Centric in culture.
What is Glenmark Pharma.'s culture and work environment like?
Glenmark Pharma. has a Founder-Centric culture with Disruptor innovation DNA and a Startup-Speed pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. Glenn Saldanha exerts significant influence on the strategic direction, characteristic of the promoter-led pharma model where the vision is closely tied to the founder's leadership.
Who leads Glenmark Pharma.?
Glenmark Pharma. is led by Glenn Saldanha (Chairman and Managing Director), a Visionary leader with 27 years of experience.
What are Glenmark Pharma.'s financials?
Glenmark Pharma. reported revenue of ₹13K Cr in FY25 with a 5-year revenue CAGR of 2.6%. Operating margin: 14.2%. Market cap: ₹60K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationDisruptor
PaceStartup-Speed
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandTechnical-Expert
LifecycleHigh Growth
Glenn Saldanha exerts significant influence on the strategic direction, characteristic of the promoter-led pharma model where the vision is closely tied to the founder's leadership.
Mandate
The company needs a visionary leader to pivot toward specialty and innovative drug portfolios to maintain growth in a competitive global pharma landscape.
The company needs a visionary leader to pivot toward specialty and innovative drug portfolios to maintain growth in a competitive global pharma landscape.
Financials
Revenue FY25₹13K Cr
PAT FY25₹1K Cr
Rev CAGR 5Y2.6%
OPM14.2%
NPM8%
ROE11.8%
ROCE18.5%
P/E57.5
Fwd P/E26.8
P/B6.4
D/E12.8
Mkt Cap₹60K Cr
Promoter49%
Institutional29.9%
Similar Culture
Could You Lead Glenmark Pharma.?
Take the Genome Benchmark →